Background. The increasing prevalence of pre-existing diabetes mellitus (DM) and especially the incidence of post-transplant diabetes mellitus (PTDM) is a disturbing tendency with far-reaching health and cost implications. We assessed the factors associated with PTDM and the impact of either condition on deathcensored graft and patient survival.
Introduction
New immunosuppressive agents have improved outcome in renal transplant patients over the last decades [1] . However, chronic allograft nephropathy and cardiovascular disease remain the most important causes of morbidity and mortality. Diabetes mellitus (DM) as underlying renal disease and post-transplant diabetes mellitus (PTDM) are two increasingly frequent entities in kidney transplant recipients [2] . Either condition may affect graft and patient survival [2] [3] [4] [5] . This decrease in survival can be explained by the increase in cardiovascular risk factors after kidney transplantation with a higher incidence of ischaemic heart disease in this population [4, 6] , together with the influence of the same risk factors (dyslipidaemia, hypertension) that play a role as non-immunological events in chronic renal allograft dysfunction [7] .
Identification of those potentially modifiable risk factors for the development of PTDM, that affect graft and patient survival, may help to develop strategies that improve outcome. In this study we retrospectively analysed a large population of kidney transplant recipients in Spain during 1990, 1994 and 1998, paying special attention to the impact of pre-and post-transplant DM on graft and patient survival. study with a last follow-up in June 2001. Only adult recipients (>17 years) receiving a single kidney that was functioning at the end of the first year after transplantation were considered.
At the time of transplantation, the following variables were recorded for each patient: source of the donor (living or cadaveric), cause of donor death, age and gender of the donor and recipient, prior transplantation, height and body weight of the recipient, presence of HBsAg and HCVAb in the donor and recipient, aetiology of end-stage renal disease, time on dialysis, peak and last panel reactivity antibodies, number of HLA mismatches and cold ischaemia time. After transplantation, the presence of delayed graft function, acute rejection, CMV infection and surgical complications were recorded.
At 3 months and yearly thereafter the following parameters were recorded: serum creatinine, 24 h proteinuria, glycaemia, cholesterol, triglycerides, arterial blood pressure, immunosuppressive regimen and treatment with hypoglycaemic drugs, lipid-lowering agents and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB).
The total sample was divided into three groups according to diabetes status. Group I (N ¼ 155) was composed of patients with DM as underlying disease. Group II (N ¼ 251) included patients with at least two evaluations of blood glucose >140 mg/dl performed at 3 months, 1, 2 and 3 years and/or patients treated with hypoglycaemic therapy between the evaluation performed at 3 months and 3 years. This group was referred to as PTDM. All other patients were included in Group III.
The data are expressed as means±SD. Comparison between groups was performed using chi-square test for categorical data and Kruskall-Wallis test for numeric or continuous data. For pairwise comparisons, Bonferroni adjustments were employed. Kaplan-Meier analysis was used to estimate overall patient and graft survival (after censoring for death). Death-censored graft and patient survival were analysed by both univariate and multivariate Cox proportional hazard models. Risk factors for PTDM were evaluated by means of multiple logistic regression models, including only those variables found to be significant in previous bivariate analyses. Since follow-up differed according to year of transplantation all analyses were based on data obtained during the first 3 years.
Results
Descriptive analysis and comparison between Groups I, II and III From a total of 3365 patients, there were 156 recipients in Group I (4.6%), 251 in Group II (7.5%) and 2958 in Group III (87.9%). The percentage of patients in Group I was significantly higher in 1998 (5.9%) than in 1990 (2.7%) (P<0.002), while the percentage of patients in Group II increased in 1998 (9.8%) as compared with 1990 (5.1%) and 1994 (6%) (P<0.0001).
Description of data regarding recipient, donor characteristics and post-transplantation data is provided in Table 1 for each group. Donor age was significantly higher in Group II than in Group III, while recipient age was higher in Group II than in Groups I and III. The percentage of males was significantly lower in Groups II and III than in Group I, while time on dialysis was longer. Recipient body mass index (BMI) and body weight were significantly higher in Group II than in the other groups; however, body weight increase during the first 3 years of follow-up was not higher in this group (data not shown). Group III showed the highest incidence of acute rejection and the lowest percentage of lipid-lowering treatment, while Group I received ACEI/ARB therapy more frequently than the other two groups. Proteinuria at 3 months was significantly lower in Group III than in Group I. No significant differences were found regarding donor cause of death, last panel reactive antibodies, HLA mismatch, cold ischaemia time, delayed graft function, serum creatinine at 3 months and 1 year or proteinuria at 1 year.
Predictors of PTDM
Results of the multiple logistic regression analysis after previous bivariate analysis are provided in Table 2 . Bivariate logistic regression results showed that the following variables were significantly associated with the presence of PTDM: year of transplantation, donor and recipient age >60 years, recipient sex (females), recipient BMI (>25 kg/m 2 ) and body weight (>65 kg), time on dialysis, immunosuppressive regimen with tacrolimus-based therapies, cholesterol >240 mg/dl and triglycerides >200 mg/dl at 3 months. Multiple logistic regression results showed that the following variables were significantly associated with the presence of PTDM: recipient age >60 years and female sex, recipient BMI (>25 kg/m 2 ), recipient body weight (>65 kg), tacrolimusbased therapies and triglyceride levels >200 mg/dl at 3 months (Table 2) . Of note, cyclosporine-based therapy in the years 1990 and 1994 showed a greater protective effect on the development of PTDM than for the year 1998.
Graft and patient survival
Kaplan-Meier 3 year survival estimates for all groups showed a lower death-censored graft survival in Group I and a higher risk of patient death for Group II, respectively, compared with Group III.
Results of Cox multivariate hazard analysis of deathcensored graft and patient survival for all groups is shown in Table 3 . As expected, donor and recipient age, cause of death, last panel reactive antibodies, delayed graft function, acute rejection, and year of transplantation were significant predictors of death-censored graft survival. Interestingly, diabetes and lipid-lowering treatment during follow-up were also independent and significant predictors. Risk of death-censored graft failure was significantly higher in Group I than in Group III (RR ¼ 1.68; 95% CI ¼ 1.14-2.47; P<0.008). With respect to patient survival, recipient age, delayed graft function, cause of donor death and again diabetes were independent and significant predictors. Risk of patient death was significantly higher in Group 
Discussion
Consistent with previous results [2] [3] [4] [5] , this observational study performed in a large Spanish population demonstrates that DM as a pre-existing disease or as a post-transplant complication has a negative impact on graft and patient prognosis. At 3 years of follow-up, patients with DM or PTDM had a higher risk of deathcensored graft loss and patient death, respectively. It is impossible to know the real incidence and impact of pre-existing diabetes on survival because only those patients with a functioning graft longer than a year were included and we had no data on patients outside this criterion. Considering that DM recipients have a high mortality in the first year after kidney transplantation [8] it can be argued that Group I is a selected one. Even so, this group showed a higher risk of deathcensored graft loss. The negative effect of DM on death-censored graft survival was unexpected considering the short time of follow-up. Although these patients have a higher early frequency of recurrence of diabetic nephropathy [9] , other factors must play a role and be analysed in future studies.
The reported incidence of PTDM in different studies varies widely from 2 to 50% [10] , due mainly to the variable and sometimes inappropriate definition of the disease [11, 12] . In this analysis we used the old definition of diabetes in the general population [13] (venous plasma glucose concentration >140 mg/dl on at least two separate occasions) or the need for hypoglycaemic therapy, because the majority of recipients were controlled before 1997 the year of the new diagnostic criteria [14] . Using the old criteria, the incidence of PTDM in the first 3 years of follow-up increased in 1998 compared with 1990 and 1994. This may be attributable to a more liberal inclusion of older and overweight transplant candidates over the last years.
Several risk factors were identified in this analysis, but only overweight and immunosuppressive therapies are modifiable (Table 2 ). In some cases it was impossible to calculate BMI, but those with a BMI >25 kg/m 2 were 1.6 times more likely to develop PTDM, and this risk rose to nearly three times (OR ¼ 2.92) with a BMI >30 kg/m 2 . When all patients were analysed by body weight similar results were obtained. This is consistent with previous findings [2, 4, 5] . It is important to take into account that we found no differences in body weight increase between the three groups during the follow-up. This means that lifestyle modification must be advised for patients on the transplant waiting list in order to avoid being overweight.
Tacrolimus has been associated more frequently with PTDM than cyclosporine (SandimmuneÕ or NeoralÕ) [15, 16] . In this analysis we observed similar results but with an interesting finding; SandimmuneÕ compared with NeoralÕ had a protective effect in the appearance of this complication. When we compared cyclosporine vs tacrolimus as two independent variables in a separate analysis, we found an increase in PTDM in the tacrolimus group (data not shown), but when we compared ( Table 2 ) the tacrolimus group with two groups of cyclosporine (SandimmuneÕ vs NeoralÕ) the higher risk was in the tacrolimus-based therapy and lower in the cyclosporine therapy used in the years 1990 and 1994 group. In Spain, NeoralÕ appeared in the middle of 1995, which implies that only patients transplanted in 1998 with cyclosporine-based therapy used the NeoralÕ formulation from the beginning and in the period of the highest dose and blood levels. It is possible than the new formulation is associated with higher blood levels, as has been postulated [2] . Unfortunately, we do not have dose and blood levels in order to confirm this hypothesis.
Female recipient and serum triglyceride levels at 3 months were other independent risk factors for PTDM. Females were not older or more overweight than males, so other factors must be analysed. High triglyceride levels as a risk factor is consistent with previous studies [4] . Higher triglyceride levels and body weight at 3 months in this group of patients is consistent with the interpretation that PTDM is the final stage of the insulin-resistance syndrome [17] before transplantation and that immunosuppressive medications play a role in completing the development of the syndrome [4, 11] . This is important because this syndrome has been postulated as a cause of chronic renal allograft dysfunction [18] . PTDM has a negative effect on patient survival (Table 3) , as has been reported previously [4] [5] [6] [7] [8] [9] . In our study, despite selecting only surviving patients with a functioning graft after 1 year of follow-up, the development of PTDM increased the risk of death by 1.5 times. This may be due to the unfavourable cardiovascular risk profile such as obesity, hypertension, etc. [4] , with a lower percentage of patients on ACEI/ARB therapy (Table 1) , which has a known beneficial effect on cardiovascular risk in nontransplanted patients [19] . This means that PTDM is an important complication after kidney transplantation that must be considered as a challenge, not only to decrease the impact on patient survival but also to reduce the high costs associated with this complication [20] . It is not possible to make recommendations about what drug to use for patients at risk of developing PTDM. Although tacrolimus increases this complication, it also has a protective effect on graft, death-censored graft and patient survival [5] . Further prospective trials considering all variables implicated in the development of PTDM and its impact on graft and patient survival are needed in order to optimize the outcome in patients after renal transplantation.
